[go: up one dir, main page]

WO2025176942A1 - Dispositif d'administration de thérapies topiques, procédé de commande du dispositif et module stérile pour le dispositif - Google Patents

Dispositif d'administration de thérapies topiques, procédé de commande du dispositif et module stérile pour le dispositif

Info

Publication number
WO2025176942A1
WO2025176942A1 PCT/FI2025/050083 FI2025050083W WO2025176942A1 WO 2025176942 A1 WO2025176942 A1 WO 2025176942A1 FI 2025050083 W FI2025050083 W FI 2025050083W WO 2025176942 A1 WO2025176942 A1 WO 2025176942A1
Authority
WO
WIPO (PCT)
Prior art keywords
therapy
sterile
application surface
volume
delivering
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
PCT/FI2025/050083
Other languages
English (en)
Inventor
Jan ANDRYS
Quan Zhou
Esko Kankuri
Jyrki VUOLA
Arthur VIEIRA
Ville SYNKKÄNEN
Aleksi KUUVA
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Helsinki
Aalto Korkeakoulusaatio sr
Original Assignee
University of Helsinki
Aalto Korkeakoulusaatio sr
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Helsinki, Aalto Korkeakoulusaatio sr filed Critical University of Helsinki
Publication of WO2025176942A1 publication Critical patent/WO2025176942A1/fr
Pending legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M35/00—Devices for applying media, e.g. remedies, on the human body
    • A61M35/003—Portable hand-held applicators having means for dispensing or spreading integral media
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H20/00—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance
    • G16H20/10—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients
    • G16H20/13—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients delivered from dispensers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2205/00—General characteristics of the apparatus
    • A61M2205/50—General characteristics of the apparatus with microprocessors or computers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2205/00—General characteristics of the apparatus
    • A61M2205/58—Means for facilitating use, e.g. by people with impaired vision
    • A61M2205/583—Means for facilitating use, e.g. by people with impaired vision by visual feedback

Definitions

  • Robotic tools can be envisioned, but they are usually of high complexity to be installed and utilized in a crowded, busy operating room environment. Moreover, robotic tools also require real-time feedback for operation, thus the requirements of accuracy, operator feedback, and quality assurance remain unaddressed.
  • a method for controlling a device for delivering therapies comprises means for delivering at least one therapy to an application surface, at least one motion sensor providing information relating to the motion and the pose of the device, at least one environmental sensor for observing the application surface, and a visual projection unit for providing user feedback to a user of the device, wherein the method comprises: controlling the means for delivering the at least one therapy based on information related to the motion and the pose of the device, a therapy delivery model, and an application surface model; and/or controlling visual user feedback provided to a user based on information related to the motion and the pose of the device, the therapy delivery model, and the application surface model.
  • Figures 2b to 2g present an illustration of an application surface and an example of the instructions provided by the visual projection unit with respect to the application surface as well as the delivery of the therapy and a visualization of the area the therapy has been delivered.
  • the environmental sensor information may also be used for observing the application of the at least one therapy on the application surface.
  • the information extracted from the sensor information may comprise either thickness of the layer applied on the application surface, only a binary information whether the at least one therapy has been applied on the application surface or not, or an information whether the thickness of the applied layer exceeds predetermined one or multiple layer thicknesses.
  • the layer thickness may be estimated using a therapy delivery model that may comprise the therapy delivery distribution for the therapy being delivered.
  • the therapy delivery model may be combined with the environmental sensor information and/or information from other models, such as the application surface model.
  • the at least one control unit 130 of the device may be configured to control the means for delivering the at least one therapy based on information related to the motion and the pose of the device, a therapy delivery model, and an application surface model.
  • the at least one control unit can be configured to provide a control information or a signal related to a control information so that the delivery of the therapy is being performed.
  • the control information may, but is not limited to, be one or more of the following: an information describing the speed of the applying of the therapy, pressure needed for the application of therapy, rotational speed of the motorized mechanism, power of the motorized mechanism.
  • the signal related to the control information may be an analogue driving signal for a motor 160 of the motorized mechanism, such as voltage or power.
  • the device is a hand-held device.
  • the device may also be controlled through an external device, such as a computer, or the device may part of robotized solution wherein the device is controlled fully automatically or wherein the robotized solution may be controlled fully using external controllers by the user.
  • the device may also have at least one physical control means, such as a button.
  • the at least one physical control means 170 may be configured to provide a controlling signal for starting the delivery of the at least on therapy.
  • the at least one physical control means 170 may be an ON/OFF latch or switch type button, but it may also be a button where the amount of the delivery is a function, e.g. linearly, of distance how far the button has been pushed.
  • Figure 2a presents an example embodiment of the topical therapy device, i.e. the device for delivering therapies.
  • the Figure 2a illustrates a device comprising a motorized spraying system 410, i.e. a motorized delivery mechanism, a syringe with therapeutic materials 412, i.e. at least one volume for the at least one therapy, switch and/or manual controller 414, i.e. physical controlling means, automatic flow control 416, motion tracking sensors 418, i.e. at least one environmental sensor and/or at least one motion sensor, and visual projection system 420.
  • the device may also comprise inputs 422 for power and air supplies.
  • the Figure 2a illustrates also the therapeutic material spray cone 424 and the visual projection cone close to the device.
  • control unit may be configured to control the visual projection unit.
  • all the units, such as control unit, visual projection unit, and computational unit, relating to the invention may be embodied in one unit or each unit may be a separate independent unit. Also, all the combinations of dividing N number of units in 1 to N different units are possible.
  • the device may comprise a further computational unit.
  • the further computational unit may be configured to generate and/or modify the application surface model based on information provided by the at least one environmental sensor.
  • the device may comprise two different parts that can be attached and detached by the user, i.e. removably attached, as well as secured with each other in a manner that the parts do not detach without the purposefully doing so, i.e. locked.
  • the so called second part i.e. sterile module
  • the parts in the sterile module comprise the following: the at least one volume for the at least one therapy, the nozzle, and a second at least one pressure delivery mechanism.
  • Parts of the device not arranged in the sterile module are configured to be arranged in the main body of the device.
  • the main body may comprise more than one module comprising the parts not arranged in the sterile module.
  • Figure 4 One example of this kind of solution is presented in Figure 4.
  • the sterile seal may be configured to be formed between the at least one pressure delivery mechanism 412 and the second at least one pressure delivery mechanism 421.
  • the sterile seal between the at least one pressure delivery mechanism and the second at least one pressure delivery mechanism may mean that there is no route for unsterile substances to get from the outer layer of the sterile module to the at least one pressure delivery mechanism nor to the parts of the main body of the device in the vicinity of the at least on pressure delivery mechanism.
  • the nozzle 428 of the device may be interchangeable to a different nozzle. By changing the nozzle to different nozzle, a different therapy distribution can be achieved with the device.
  • the nozzle 428 may also have at least one channel for providing pressurized gaseous substance, such as pressurized air, for forming therapy distribution in a form of spray to be output from the nozzle and on the application surface.
  • the sterile module comprises at least one holder configured to hold the at least volume for the at least one therapy.
  • the sterile module comprises an input for pressurized gaseous substances, wherein the input is connected via at least one channel to the nozzle.
  • the at least one volume for the at least one therapy comprised in the sterile module may be a syringe.
  • the syringe may be attached and/or detached from the sterile module.
  • Figure 5 presents example operation of one embodiment of the invention relating to measurement and estimation of real time motion.
  • the inertial measurement unit 510 acts as the at least one motion sensor in the example providing position data for estimating 520 the pose and motion, especially the motion at high speed.
  • the estimated pose and motion are used for real-time estimation input to sensor fusion module 550.
  • the depth camera 520 that acts as the at least one environmental sensor, provides depth/image data for calculating 540 pose and motion respective to the application surface.
  • the calculated pose and motion with respective to the application surface are input as well to the sensor fusion module 550.
  • the sensor fusion module 550 provides real-time motion data 560 for the device.
  • Figure 6 presents example operation of one embodiment of the invention relating to the generation of the application surface model.
  • the operation is commenced after a pre-scan 610, wherein the surface to be scanned is prepared for the scanning, with manually scanning 620 the surface using the sensors in the device, especially the environmental sensors.
  • a surface model is created 630.
  • the surface model 640 may be a 3D model, but also higher dimensions may be used in the model.
  • Some of the example dimensions that may be included in the surface model in addition to the physical dimensions are color information at different wavelengths, healing procedure of the surface area based on the previous scanning, and severeness of a burn wound on the surface.
  • an application surface model is output for the generation of the application surface model.
  • Figure 7 example operation of one embodiment of the invention relating to device control during the application which can be utilized by the one embodiment of the invention.
  • the operator moves 712 the device near application surface.
  • an estimation 714 of real-time pose and motion may be created.
  • the estimation may also provide real-time motion data. If the pose and the motion are correct 716 it may be checked whether an automatic or manual delivery 718 is in use. In case only one of the automatic or manual delivery is enabled in the device, that delivery method is used. If the pose and motion were not correct, the delivery may be stopped, and operation of an indicator projection module 750 may be performed.
  • a trigger is pressed 720: if not the delivery may be stopped or if it is pressed the delivery may be controlled by the delivery module 770, i.e. the spray module.
  • the delivery is controlled by the delivery module 770.
  • the delivery is stopped, when the trigger is not pressed, it may be checked whether the pose and the motion are correct, and the operation may be continued thereon.
  • there may be a state projection module 760.
  • the indicator projection module 750 may comprise a learning model of the operator, i.e. the user, behaviour with regards to indicators.
  • the learning model inputs may comprise real-time motion data, real-time indicator data, and/or operator indicator behavior.
  • the learning model may provide as an output operator indicator behaviour.
  • the indicator projection module may also comprise a model for behaviour aware projection of the indicator on surface for correcting directions, pose, distance and speed after the delivery is stopped if the pose and motion were not correct. This model may input the operator indicator behaviour and real-time motion data.
  • the indicator projection module provides instructions for the user to control the movement of the device near application surface.
  • the spray module may comprise models for application state estimator and for surface aware spray of application material to surface.
  • the model for surface aware spray may be used when automatic mode is detected or the trigger is pressed.
  • the model for the surface aware spray may input application surface model, real-time motion data, delivery model, and/or application state, and it may output delivery data.
  • the model for the application state estimator may input delivery data, delivery model, and/or application surface model, and it may output application state.
  • the state projection module may comprise learning model of operator behaviour with regards to states and/or a model for behaviour aware projection of current application state.
  • the learning model may input real-time motion data, operator state behaviour, real-time state projection data and/or application state, and it may output operator state behaviour.
  • the model for behaviour aware projection may input operator state behaviour and/or application state, and it may output real-time state projection data and provide instructions for the operator to move the device near the application surface.
  • the application surface model may be used for projection of surface boundary and properties for instructing the operator to move the device near application surface.
  • a global long-term model 780 may output operator behaviour and surface aware spray for the different models in the state projection module, delivery module, and indicator projection module to use as an input.
  • the global long-term model may provide input for the estimation of real-time motion and pose, as well.
  • Figure 8 presents example operation of one embodiment of the invention relating to a global long-term model 780, 880.
  • the global long-term model may provide properties as an input for different application cases at different sites 810, 812, 814, i.e. locations. This also means that the global term model may use different application cases from various locations, such as hospitals or other places where the delivery of the therapy may be performed to learn of different behaviours of different users.
  • the properties provided as an input may comprise operator state behaviour, application surface model, real-time indicator data, delivery model, delivery data, application state, real-time motion data, real-time state projection data, operator indicator behaviour and/or validated application results.
  • the global model may take properties as an input and/or output properties to be used as inputs in the application.
  • the means for delivering the at least one therapy using device is controlled based on the information related to the motion and pose of the device, a therapy delivery model, and an application surface model.
  • the controlling may be preferably performed programmatically, but a mechanical or other type of controlling method is also possible.
  • the visual user feedback using device is controlled based on the information related to the motion and the pose of the device, the therapy delivery model, and the application surface model.
  • the controlling may be preferably performed programmatically, but a mechanical or other type of controlling method is also possible.
  • the application surface models may be stored and different application surface models calculated during different deliveries of at least one therapy may be compared.
  • the comparison of the different application surface models may be performed for monitoring the changes in the application surface based on the different application surface models. For example, an application surface model taken during the lates delivery of the at least one therapy may be compared to at least on earlier stored application surface model. The comparison may provide information based on the healing of the application surface.
  • the invention provides a tool and a software solution that can deliver in a controlled manner advanced therapies, while providing operator feedback as reflected on the application surface such as the surface of the wound, for example stem cells and biomaterials, separately or as a combination onto the wounds and skin surfaces.
  • the intelligent sprayer can visually guide the operator during the application procedure of the therapy, such that the operator can deposit e.g. an even layer (or any desired thickness profile) of the therapy on the wound surface at desired locations.
  • Such controllability, feedback, and programmability are not found in existing devices, which can merely apply materials upon the experience of the operator - leading to poor control of the therapy, inaccurate dosing, and eventually, for example in the case of wounds, an erratic healing process.
  • the intelligent sprayer consists of a motorized spraying mechanism and related control electronics, motion sensors such accelerometers, gyroscopes for multiple degrees-of-freedom, camera and/or other environmental sensors, a visual projection unit and other visual, audio and vibration transducers for user feedback, computational units and software, mechanical switches for user inputs such as on/off triggers and spraying triggers. Operations can be controlled in an integrated manner or through wired or wireless communication link to external computer. Power source is through a cable or a battery.
  • the primary visual feedback projected on the application surface includes information regarding the application instrument’s angle, movement speed, and distance relative to the tissue surface, the real-time estimation of the amount of spray, and indicator/warning of areas requiring particular attention.
  • Other feedback such as audio, vibration and other visual display on the spray device or external assistive devices will enhance the primary visual feedback for warning of unfavourable condition such as speed out of range, position out of boundary, spraying ceased, and other situation require the operator’s attention.
  • the intelligent sprayer can work in different modes, e.g.:
  • the intelligent sprayer visually guides the operator during the application of cell therapy or other biomaterials, where the operator is responsible for the spray.
  • the intelligent sprayer guides the operator to position the sprayer correctly, and automatically controls the spraying process when the parameters are good.
  • the operator is only responsible of start and stopping the procedure and move the sprayer under the instruction of the intelligent sprayer.
  • the spray device will also take into account the needs of uneven wounds and skin surfaces, e.g., in many chronic wounds by employing models the surface generated online or offline.
  • the application of spray will be at a close distance based on the 3D morphology of the wound surface.
  • the intelligent spray device or the spray head can be mounted on a 3 or 6 degrees of freedoms robotic structure to allow autonomous position and pose control of the spray position and direction.
  • Example therapies e.g. liquid therapies such as bio-material liquids, to be used with the device according to the invention comprise the different biologicals and materials, but is not limited to these, disclosed in the following paragraphs.
  • examples of different embodiments of the use of the therapies are disclosed as well.
  • Disclosed biologicals and other materials may be used each independently or in different combinations with other, disclosed and/or undisclosed biologicals and other materials.
  • Hydrogels or other flowable materials or biomaterials or their components such as fibrinogen/thrombin or fibrin-based biomaterials, cellulose-based hydrogels for example bacterial or plant-derived cellulose or nanocellulose, hydroxyapatite, chitosan- and chitinbased biomaterials, silk, gelatin, flowable biopolymers such as hydrated biopolymers using xylans.
  • Recombinant proteins or their fragments or protein mixtures such as growth factors, cytokines, cytokine antagonists. Protein aggregates or hybrid recombinant proteins.
  • Factors or compounds with antimicrobial activity such as antimicrobial peptides and their derivatives or organic or inorganic particles such as silver or nanosilver particles.
  • Active compounds such as those with antimicrobial activity, cell proliferation or migration stimulating activity, anti-fibrotic factors or compounds.
  • Factors compounds, proteins, fragments or others with angiogenic, anti- angiogenic, anti-inflammatory, or hemostatic activity.
  • Vitamins inorganic compounds or mixtures.
  • Organic or inorganic chemicals such as acids, bases, various pH buffer compositions such as bicarbonate solutions.
  • Natural or recombinant molecules such as proteins (such as extracellular proteins, laminins, collagen), peptides, protein fragments, lipids, carbohydrates, various natural or artificial polymers or any length.
  • Lipids Lipids, polymers, carbohydrates/polysaccharides etc. Hormones, hormone derivatives, hormone analogues. Autologous, allogeneic or xenogenic cells, tissues or their fragments or derived factors, extracellular materials, or matrix-derived components.
  • Viral vectors or particles such as adeno-associated viral vectors for nucleic acid e.g. RNA or DNA delivery.
  • Nanoparticles or other formulations such as lipid nanoparticles used for RNA/DNA delivery.
  • compositions comprised of or containing agents such as metals, ceramics, plastics, glass, silicone, (poly)acrylates, (poly)urethanes, stainless steel, dacron, titanium, aluminium or similar materials.
  • Metal-based materials polymer-based materials, ceramics-based materials, natural or synthetic materials, inorganic-based materials, organic-based (lipid, protein/peptide, carbohydrate, organic compounds or molecules), or hybrid materials.
  • Combinations, composites, polymers and other formulations such as various types of delivery particles, pharmaceutical preparations, controlled-release preparations, biocomposites, nanoformulations, dynamic 4D or 5D formulations, shape-morphing systems etc) of the above or others.
  • formulations such as various types of delivery particles, pharmaceutical preparations, controlled-release preparations, biocomposites, nanoformulations, dynamic 4D or 5D formulations, shape-morphing systems etc.
  • Formulations with different or variable porosities, flow capacities, rheological properties, polymerization capacities or abilities, degradability or other properties modifiable by factors such as spray or extrusion administration, pressure, light, temperature, ultrasound.
  • targeted tissue depths and some controlling related features are described in the following paragraphs.
  • the different features disclosed in the following paragraphs may be or may not be combined with each other’s.
  • Subcutaneous tissue highly variable, depends on amount of fat, roughly 2- 31 mm
  • Burn wounds are more planar with a larger surface area, whereas chronic wounds, decubitus ulcers/pressure ulcers are deeper and extend even to underlying muscle and bone.
  • maximize efficacy by controlling dosing/providing exactly the desired dose, providing the desired coverage considered optimal for the therapeutic (e.g. droplet delivery of keratinocytes to achieve high cell concentrations/aggregates in which the cells perform best for proliferation and migration at desired areas), optimizing the properties of therapeutics, reducing side effects, avoiding tolerance or resistance to the therapeutic, maximizing use and minimizing wastage, to achieve a predictable and consistent therapeutic effect, to improve patient compliance, to avoid adverse effects and maximizing therapeutic effects, and — for some therapeutics — minimizing absorption and thus systemic exposure.
  • the instrument uses visual signals projected on the application surfaces, such as wound and skin surface or other application surfaces.
  • the visual signals can include graphic arrows that may vary with colour, frequency and shape/pattern that guiding the operate to act properly, e.g., apply more, or avoid certain area, to achieve the desired delivery of the application materials.
  • More rich signals e.g., the estimated application amount in graphical manner can also be projected onto the surfaces.
  • the visual signal gives reflection on the human operators to operate according to his/her plan based on one’s expertise.
  • the device will also learn the reaction/behaviour of the human operator based on its current and historical behaviour such that the device will optimize the visual signal (both indicators and progress display) in timeliness and types such that the application results are better.
  • IMU will give position data at high frequency and short time latency for motion estimation algorithms, such as Kalman filter or alike, where the motion of the device/operator can be known.
  • Depth camera such as stereo vision camera or Lidar, in combination of vision camera, will be used to provide the information of the application surface and estimate the relation between the application device and the surface and greater latency and smaller frequency then IMU.
  • the information provided by the camera(s) will be more accurate and richer. So the motion of the device/operator will be estimated together using both or either techniques depending on the application cases/requirements and cost of the device.
  • nozzles required for different types of administration depending on desired area or volume coverage, type of product or material applied (e.g. solution, suspension, granule sizes, cell or aggregate size/volumes, cell or material sensitivity to pressure/shear stress, rheological properties, viscosity etc.), desired therapeutic product end-features (such as porosity, shape, droplet size etc.).
  • product or material applied e.g. solution, suspension, granule sizes, cell or aggregate size/volumes, cell or material sensitivity to pressure/shear stress, rheological properties, viscosity etc.
  • desired therapeutic product end-features such as porosity, shape, droplet size etc.
  • the surface aware spray application will use motor (step or DC servo) to control the spraying of application material, where the pressure will be initially constant (later can be controlled as well).
  • the control of the spraying will at least be based on the spray model (derived in a dedicated study by varying the position, pose, distance, velocity and pushing velocity of the spray) and the application surface model (see the pre-scan diagram above).
  • the spray will be surface and position aware, i.e., the spray power will be controlled based on the motion and pose of the device and the spray model and surface model, (see the spray module in the figure below)
  • the behaviour aware projection of indicators will learn how the human reacts to the indicator on the application surface, and improve the indicator timeliness and patterns to improve spray results, (the indicator projection module in the figure below).
  • the behaviour aware project of application state will learn how the human reacts to the state display on the application surface, and improve the state display timeliness and patterns to improve spray results, (the state projection module in the figure below).) All data of each application case, including the spray model used in the application, the pre-scanned application surface model, and real-time application data, including the real-time motion data (position, pose, velocity, etc), real-time indicator data, the learnt operator indicator behaviour, the application data, the application state, the real-time spray projection data, operator state behaviour data will be recorded.
  • the mode of the device can be switched.
  • the method will also be extended to application different from spraying or other manual application of medical therapy, for example, using extrusion for application materials to surfaces.
  • the behaviour aware projection of indicators and surface and motion aware control of the extrusion will also be applicable.

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Primary Health Care (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Medical Informatics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Anesthesiology (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Infusion, Injection, And Reservoir Apparatuses (AREA)

Abstract

L'invention concerne un dispositif (100) d'administration de thérapies, par exemple des thérapies liquides telles que des liquides de biomatériau, et un procédé de commande du dispositif, le dispositif comprenant des moyens pour administrer au moins une thérapie à une surface d'application ; au moins un capteur de mouvement, tel qu'un accéléromètre et/ou un gyroscope, pour fournir des informations relatives au mouvement et à la pose du dispositif ; au moins un capteur environnemental (110) pour observer la surface d'application et fournir des informations pour un modèle de surface d'application ; une unité de projection visuelle (120) pour fournir une rétroaction d'utilisateur à un utilisateur du dispositif ; et au moins une unité de commande (130) configurée pour commander les moyens pour administrer l'au moins une thérapie sur la base d'informations relatives au mouvement et à la pose du dispositif, d'un modèle d'administration de thérapie et d'un modèle de surface d'application.
PCT/FI2025/050083 2024-02-23 2025-02-21 Dispositif d'administration de thérapies topiques, procédé de commande du dispositif et module stérile pour le dispositif Pending WO2025176942A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FI20247024 2024-02-23
FI20247024 2024-02-23

Publications (1)

Publication Number Publication Date
WO2025176942A1 true WO2025176942A1 (fr) 2025-08-28

Family

ID=94928124

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/FI2025/050083 Pending WO2025176942A1 (fr) 2024-02-23 2025-02-21 Dispositif d'administration de thérapies topiques, procédé de commande du dispositif et module stérile pour le dispositif

Country Status (1)

Country Link
WO (1) WO2025176942A1 (fr)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150057623A1 (en) * 2013-08-23 2015-02-26 Elwha Llc Systems, Methods, and Devices for Delivering Treatment to a Skin Surface
US20170274159A1 (en) * 2015-06-03 2017-09-28 Novopyxis, Inc. Fluid delivery devices and methods

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150057623A1 (en) * 2013-08-23 2015-02-26 Elwha Llc Systems, Methods, and Devices for Delivering Treatment to a Skin Surface
US20170274159A1 (en) * 2015-06-03 2017-09-28 Novopyxis, Inc. Fluid delivery devices and methods

Similar Documents

Publication Publication Date Title
CN109153181B (zh) 用于生物产品的分配设备和系统
US11938674B2 (en) Modular fabrication systems and methods
US9723866B2 (en) System and method for solid freeform fabrication of edible food
US9965656B2 (en) Methods and apparatus for computer-aided tissue engineering for modeling, design and freeform fabrication of tissue scaffolds, constructs, and devices
US11724450B2 (en) Systems and methods for printing a fiber structure
CN108853702B (zh) 一种新型智能药物喷洒系统
US20250276489A1 (en) Systems and methods for printing a core fiber
WO2021081672A1 (fr) Systèmes et procédés d'impression d'une fibre noyau-enveloppe
KR20220113716A (ko) 바이오프린팅 시스템
WO2025176942A1 (fr) Dispositif d'administration de thérapies topiques, procédé de commande du dispositif et module stérile pour le dispositif
RU2814949C1 (ru) Роботизированная медицинская система и манипулятор для 3D-биопечати для полнослойного закрытия кожного дефекта
Kim et al. Aspiration-assisted bioprinting of spheroids
CN1609210A (zh) 一种细胞－材料单元的三维受控堆积成形方法
Fortunato et al. In Situ Bioprinting—Current Applications and Future Challenges
Nithianantham et al. Tubulin Cofactors Form a Multi-Protein Platforms that Regulate the Soluble Tubulin Pool and Promote Microtubule Polymerization

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 25710909

Country of ref document: EP

Kind code of ref document: A1